Aldeyra Therapeutics ALDX Cash Flow Statement (2013-2026)

NASDAQ ALDX
$0.73 +0.07 (+10.40%)
At close: Oct 20, 2026 · 4:00 PM EDT
Reported Financials

Aldeyra Therapeutics Quarterly Cash Flow Statement

Periods 54 quarters
Latest Jun 2026

Aldeyra Therapeutics reported cash from operations of -$4.59M and free cash flow of -$4.59M for the quarter ended Jun 2026, up 46.4% year over year. This cash flow statement covers 54 quarters of results from Mar 2013 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-15.79M-15.75M-16.79M-17.78M-14.55M-12.90M-15.62M-8.99M-8.19M-4.75M-8.08M-16.85M-15.11M-15.81M-9.93M-9.77M-7.69M-6.46M-3.45M-5.45M
Depreciation and DepletionDep. & Depletion
0.07M0.06M0.06M0.06M0.07M0.07M0.07M0.06M0.06M0.07M0.06M0.06M0.06M0.06M0.06M0.06M0.06M0.07M0.07M0.07M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
0.08M0.08M0.08M0.08M0.08M0.08M0.09M0.10M0.10M0.07M0.06M0.04M0.04M0.04M0.07M0.05M0.05M0.05M0.05M
Depreciation & Amortization (CF)Dep. & Amort.
0.07M0.06M0.06M0.06M0.07M0.07M0.07M0.06M0.06M0.07M0.06M0.06M0.06M0.06M0.06M0.06M0.06M0.07M0.07M0.07M
Share-based CompensationStock Comp.
1.42M0.98M1.94M1.29M2.24M2.82M4.19M1.57M0.79M-0.80M1.55M1.94M3.23M1.26M2.22M0.20M2.58M1.09M-0.99M1.64M
Deferred Taxes
Other non-cash itemsOther Non-Cash
0.27M
Change in Working Capital
Change in Account PayablesChange Payables
-0.63M0.55M1.42M-0.67M-0.47M-1.17M0.30M-0.16M-0.02M1.09M-1.06M-0.03M-0.07M-0.01M0.17M0.68M-1.02M0.15M-0.02M0.00M
Change in Accured ExpensesChange Accured Exp.
3.65M0.06M2.94M-2.87M-1.33M2.46M-2.19M-5.14M-0.69M-0.06M0.49M-0.35M3.05M1.82M-5.17M0.19M-0.80M-0.56M-1.24M0.17M
Change in Other Operating AssetsOther Assets Change
-1.05M-2.44M2.53M-1.44M0.10M2.57M-3.73M0.81M0.07M1.11M2.82M-2.49M-1.34M-1.06M-0.25M-0.46M-0.05M-0.42M-0.47M1.02M
Change in Other Operating LiabilitiesOther Liabilities Change
Other Working Capital ChangesOther WC Changes
1.05M2.44M-2.53M1.44M-0.10M-2.57M3.73M-0.81M-0.07M-1.11M-2.82M2.49M1.34M1.06M0.25M0.46M0.05M0.42M0.47M-1.02M
Cash from OperationsCash from Ops.
-8.43M-11.58M-12.87M-19.96M-12.57M-11.23M-9.44M-13.36M-8.02M0.50M-9.97M-13.22M-7.97M-12.04M-12.47M-8.56M-7.02M-5.30M-5.11M-4.59M
Investing Activities
Capital ExpendituresCapex
0.02M
Change in Property, Plant and EquipmentChange in PP&E
-0.02M
Acquisitions
Net of Acquisitions & DivestmentsNet Acquisitions
Purchase of InvestmentsInvestments Purchased
58.02M29.94M4.98M30.38M30.24M14.74M21.56M15.71M24.55M
Sale and Maturity of InvestmentsInvestments Sold
12.00M24.00M27.00M30.00M12.00M20.00M20.00M23.00M24.00M25.00M16.00M
Cash from Investing ActivitiesCash from Investing
-58.03M-17.94M19.02M27.00M30.00M-30.38M-18.24M5.26M-1.56M7.29M-0.55M25.00M16.00M-0.02M
Financing Activities
Change in Capital Stock
Common Stock IssuedStock Issued
0.06M0.02M1.20M0.05M0.01M0.22M0.03M0.02M-0.20M0.57M1.00M0.12M0.07M
Net Shares Issued and RepurchasedNet Shares Issued
0.06M0.02M1.20M0.05M0.01M0.22M0.03M0.02M-0.20M0.57M1.00M0.12M0.07M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.06M0.02M1.20M0.05M0.01M0.22M0.03M0.02M-0.20M0.57M1.00M0.12M0.07M
Other financing activitiesOther financing
-0.53M-1.58M-0.56M
Cash from Financing ActivitiesCash from Financing
0.06M0.02M1.20M0.05M0.01M-0.32M-1.01M0.02M-0.20M0.01M1.00M0.12M0.07M-15.30M
Additional items
Change in Cash
-8.37M-11.58M-70.88M-37.90M7.64M15.77M20.61M-13.35M-8.34M-0.51M-40.33M-31.46M-2.91M-13.59M-4.18M-9.11M18.10M10.70M-5.04M-19.91M
Ending Cash Balance
241.37M229.79M158.91M121.01M128.65M144.42M165.03M151.68M143.33M142.82M102.49M71.03M68.12M54.53M50.35M41.24M59.34M70.04M65.00M45.09M
Free Cash FlowFCF
-8.43M-11.58M-12.89M-19.96M-12.57M-11.23M-9.44M-13.36M-8.02M0.50M-9.97M-13.22M-7.97M-12.04M-12.47M-8.56M-7.02M-5.30M-5.11M-4.59M
Net Cash FlowNCF
-8.37M-11.58M-70.88M-37.90M7.64M15.77M20.61M-13.35M-8.34M-0.51M-40.33M-31.46M-2.91M-13.59M-4.18M-9.11M18.10M10.70M-5.04M-19.91M
Interest Paid
0.33M0.33M0.32M0.33M0.33M0.36M0.40M0.43M0.44M0.44M0.44M0.44M0.44M0.42M0.42M0.43M0.43M0.42M0.42M0.14M

Aldeyra Therapeutics Cash Flow Statement API

Pull Aldeyra Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=ALDX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY